Cyclin-Dependent Kinase Inhibitor 2A (CDKN2A/P16) Polymorphisms and Risk of Pancreatic Neuroendocrine Tumors

#1100

Introduction: Pancreatic neuroendocrine tumors (PNETs) represent only 1% of all pancreatic neoplasms by incidence, but 10% by prevalence. Family history of cancer is the only established risk factor so far. The impact of germline genetic variability on PNET risk is poorly understood.

Aim(s): In this study we analyzed the genetic polymorphisms of the cyclin-dependent kinase inhibitor 2A (CDKN2A/p16) gene with respect to the risk of developing the disease.

Materials and methods: We genotyped 18 single nucleotide polymorphisms (SNPs) belonging to the CDKN2A gene region in 324 PNET cases and 2126 controls recruited within the PANcreatic Disease ReseArch (PANDoRA) consortium, a well established multi-centric study.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: Canzian F

Authors: Campa D, Rizzato C, Capurso G, Delle Fave G, Gazouli M,

Keywords: pancreatic neuroendocrine tumor, p16, cdkn2a, genetic polymorphisms, SNP, association, susceptibility,